Drug Profile
Dextromethorphan/esbupropion - Axsome Therapeutics
Alternative Names: AXS-09Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Axsome Therapeutics
- Class Morphinans; Propiophenones; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Nicotinic receptor antagonists; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in CNS-disorders(In volunteers) in USA (PO, Tablet)
- 27 Apr 2021 Phase I development is still ongoing for CNS disorders (In volunteers) in USA (PO)
- 28 Mar 2021 No recent reports of development identified for phase-I development in CNS-disorders(In volunteers) in USA (PO, Tablet)